Patents by Inventor Simon B. Lang

Simon B. Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TROP2 BINDERS AND CONJUGATES THEREOF
    Publication number: 20240358847
    Abstract: TROP2 binders and variants thereof are described. In a specific embodiment, the TROP2 binders that are antibodies that preferentially bind high-expressing TROP2 cells over low-expressing TROP2 cells and conjugates thereof comprising the TROP2 binders conjugated to a payload are described.
    Type: Application
    Filed: April 22, 2024
    Publication date: October 31, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Minilik Angagaw, Edward Paul Bowman, Ming-Tang Chen, Laurence Fayadat-Dilman, Malgorzata A. Gil, Marlene C. Hinton, Zhong Hua, Rebecca Elizabeth Johnson, Simon B. Lang, W. Michael Seganish, Andrew B. Waight
  • AURISTATIN LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240207425
    Abstract: The present disclosure is directed to linker-payloads, and pharmaceutically acceptable salts, solvates, or stereoisomer thereof, comprising a structure of formula I: The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds, intermediates thereof, and compositions in the prevention or treatment of cancers and/or tumors.
    Type: Application
    Filed: December 12, 2023
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Manoj B. Charati, John A. Flygare, Rebecca Elizabeth Johnson, Simon B. Lang, W. Michael Seganish
  • EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240208987
    Abstract: The present disclosure is directed to linker-payloads, and salts (including pharmaceutically acceptable salts), solvates, or stereoisomers thereof, comprising a structure of formula I: The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds, intermediates thereof, and compositions in the prevention or treatment of cancers and/or tumors.
    Type: Application
    Filed: October 23, 2023
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Vlad Bacauanu, Manoj B. Charati, Sijie Chen, Rebecca Elizabeth Johnson, Simon B. Lang, Christian L. Morales, Ryan Quiroz, W. Michael Seganish, Nancy Zepeda
  • EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240116945
    Abstract: The present disclosure is directed to alcohol and amine containing exatecan derivatives, and pharmaceutically acceptable salts or solvates thereof, comprising a structure of formula I: wherein X is defined in the disclosure. The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of cancers and/or tumors.
    Type: Application
    Filed: August 31, 2023
    Publication date: April 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Vlad Bacauanu, Manoj B. Charati, Rebecca Elizabeth Johnson, Simon B. Lang, Ryan Quiroz, W. Michael Seganish, Song Yang, Nancy S. Zepeda
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20230416227
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 28, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Maoqun Tian, Salman Jabri, Galen Paul Shearn-Nance, Rongze Kuang, Zhiqiang Zhao, Zhicai Wu
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20230286958
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: June 10, 2021
    Publication date: September 14, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Salman Jabri, Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Brandon M. Taoka, Maoqun Tian, Galen Paul Shearn-Nance, Rongze Kuang, Matthew J. Lombardo, Zhicai Wu, Zhiqiang Zhao
  • PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS
    Publication number: 20230219962
    Abstract: The present invention relates to novel Pyrazolo[4,3 -d]Pyrimidine Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one Pyrazolo[4,3-d]Pyrimidine Derivative, and methods of using the Pyrazolo[4,3-d]Pyrimidine Derivatives for treating or preventing a cellular proliferative disorder in a patient.
    Type: Application
    Filed: June 3, 2021
    Publication date: July 13, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jianming Bao, Natalija Cernaka, Scott A. Hollingsworth, Madeleine Eileen Kieffer, Simon B. Lang, Akash M. Patel, W. Michael Seganish